Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Abiomed, Inc.    ABMD

ABIOMED, INC.

(ABMD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/20/2020 10/21/2020 10/22/2020 10/23/2020 10/26/2020 Date
277.53(c) 272.6(c) 278.5(c) 281.42(c) 284.33 Last
141 637 245 345 292 447 202 810 112 237 Volume
-1.40% -1.78% +2.16% +1.05% +1.03% Change
More quotes
Financials (USD)
Sales 2021 843 M - -
Net income 2021 181 M - -
Net cash position 2021 541 M - -
P/E ratio 2021 68,7x
Yield 2021 -
Sales 2022 1 015 M - -
Net income 2022 243 M - -
Net cash position 2022 838 M - -
P/E ratio 2022 52,5x
Yield 2022 -
Capitalization 12 677 M 12 677 M -
EV / Sales 2021 14,4x
EV / Sales 2022 11,7x
Nbr of Employees 1 536
Free-Float 92,2%
More Financials
Company
Abiomed, Inc. specializes in the development, manufacturing and marketing of medical devices to assist or replace the pumping function of the failing heart. Net sales break down by activity as follows: - product sales (96.4%): heart pumps (Impella brand); - service provision (3.6%): including preventive maintenance services. The United States account for 86.4% of net sales.  
More about the company
Notations Surperformance© of Abiomed, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about ABIOMED, INC.
07:56aABIOMED : FDA Grants 510(k) Clearance for Abiomed's Innovative Cardiopulmonary S..
BU
10/19ABIOMED : Data Presented at TCT Connect Finds Pre-PCI Use of Impella for AMI Car..
AQ
10/16ABIOMED : Largest Study of Hemodynamically Supported High-Risk PCI Patients Find..
AQ
10/16ABIOMED : to Host a Virtual Meeting to Discuss New Clinical Data Presented at TC..
AQ
10/16ABIOMED : Studies Presented at TCT Connect Associate Higher Survival With Early ..
BU
10/16ABIOMED : Data Presented at TCT Connect Finds Pre-PCI Use of Impella for AMI Car..
BU
10/15ABIOMED : to Host a Virtual Meeting to Discuss New Clinical Data Presented at TC..
BU
10/15ABIOMED : Largest Study of Hemodynamically Supported High-Risk PCI Patients Find..
BU
10/14ABIOMED : Restore EF Study Demonstrates Impella-Supported High-Risk PCI Improves..
BU
10/09ABIOMED : TCT Connect to Highlight How Impella Enables Improved Outcomes for Hig..
AQ
10/09ABIOMED : Second Quarter Fiscal 2021 Earnings and Conference Call Notification
AQ
10/08ABIOMED : Second Quarter Fiscal 2021 Earnings and Conference Call Notification
BU
10/08ABIOMED : TCT Connect to Highlight How Impella Enables Improved Outcomes for Hig..
BU
09/15ABIOMED : to Hold Fireside Chat at the Raymond James North American Equities Con..
AQ
09/14ABIOMED : to Hold Fireside Chat at the Raymond James North American Equities Con..
BU
More news
News in other languages on ABIOMED, INC.
10/19ABIOMED : Restore EF-Studie zeigt Verbesserung der linksventrikulären Ejektionsf..
10/19ABIOMED : Daten, die bei TCT Connect vorgestellt worden sind, zeigen, dass ein P..
10/16ABIOMED : Auf TCT vorgestellte Studien bringen höhere Überlebensrate mit früher ..
10/16ABIOMED : Les données présentées lors du TCT Connect révèlent que l'utilisation ..
10/16ABIOMED : Les études présentées lors du TCT Connect démontrent que l'identificat..
More news
Chart ABIOMED, INC.
Duration : Period :
Abiomed, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABIOMED, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 315,40 $
Last Close Price 281,42 $
Spread / Highest target 29,7%
Spread / Average Target 12,1%
Spread / Lowest Target -22,9%
EPS Revisions
Managers
NameTitle
Michael R. Minogue Chairman, President & Chief Executive Officer
David M. Weber Chief Operating Officer & Senior Vice President
Todd A. Trapp Chief Financial Officer & Vice President
Thorsten SieŖ Chief Technology Officer & Vice President
Charles A. Simonton Chief Medical Officer & Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ABIOMED, INC.64.97%12 677
THERMO FISHER SCIENTIFIC47.80%189 950
DANAHER CORPORATION51.59%165 276
INTUITIVE SURGICAL, INC.24.42%86 460
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.95.16%64 541
BOSTON SCIENTIFIC CORPORATION-17.80%53 178